Passage Bio, Inc.
NASDAQ Global SelectTotal Valuation
Passage Bio, Inc. carries a market capitalization of 19.15M, placing it among publicly traded companies globally. Its enterprise value stands at -2.58M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 19.15M |
| Enterprise Value | -2.58M |
Share Statistics
Passage Bio, Inc. currently has 3.21M shares outstanding.
| Shares Outstanding | 3.21M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.04 |
| P/TBV Ratio | 2.13 |
| P/FCF Ratio | -0.82 |
| P/OCF Ratio | -0.82 |
Financial Position
Passage Bio, Inc. maintains a current ratio of 1.73, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.73 |
| Quick Ratio | 1.66 |
| Debt / Equity | 48.97 |
| Debt / EBITDA | -0.15 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -61.53 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Passage Bio, Inc.'s stock has declined approximately -38.19876% over the past 52 weeks. The 50-day moving average sits at 6.65, while the 200-day moving average is 8.51.
| Beta (5Y) | N/A |
| 52-Week Price Change | -38.19876% |
| 50-Day Moving Average | 6.65 |
| 200-Day Moving Average | 8.51 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -37.55M, while operating income came in at -38.21M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -38.21M |
| Pretax Income | -37.68M |
| Net Income | -37.68M |
| EBITDA | -37.55M |
| EBIT | -38.21M |
| Earnings Per Share (EPS) | -11.83 |
Balance Sheet
Passage Bio, Inc. holds 33.34M in cash and equivalents against 5.76M in total debt, resulting in a net debt position of -33.34M. Total book value stands at -712.32M, with working capital of 14.64M providing operational flexibility.
| Cash & Cash Equivalents | 33.34M |
| Total Debt | 5.76M |
| Net Debt | -33.34M |
| Equity (Book Value) | -712.32M |
| Book Value Per Share | -223.68 |
| Working Capital | 14.64M |
Cash Flow
Passage Bio, Inc. produced -30.65M in operating cash flow over the past twelve months.
| Operating Cash Flow | -30.65M |
| Capital Expenditures | N/A |
| Free Cash Flow | -30.65M |
| FCF Per Share | -9.62 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.09 |
| FCF Yield | -122.60 |
Stock Splits
Passage Bio, Inc.'s most recent stock split took place on July 14, 2025 with a 20:1 split ratio.
| Last Split Date | 7/14/2025 |
| Split Ratio | 20:1 |
Scores
Passage Bio, Inc. posts an Altman Z-Score of -29.72, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -29.72 |